Ductal, Lobular, and Medullary Tumors

These are types of cancer that start in specific parts of the breast. 'Ductal' means it starts in the milk ducts. 'Lobular' means it starts in the lobules where milk is made. 'Medullary' means it starts in the supporting tissue. These are the most common types of breast cancer.

Condition

What people with Ductal, Lobular, and Medullary Tumors report

Every report comes from a Lived member, sent anonymously.

Have you had Lumpectomy for Ductal, Lobular, and Medullary Tumors?

NameHow it went

About Ductal, Lobular, and Medullary Tumors

What It Is

Ductal, lobular, and medullary tumors are a group of growths, usually cancers, named for where they start or how they grow. Most are in the breast. The breast contains ducts, thin tubes that carry milk to the nipple, and lobules, small sacs where milk is made. Ductal tumors begin in the cells lining the ducts and lobular tumors in the cells lining the lobules. Medullary describes a rare breast cancer that grows as a soft, well-defined mass packed with immune cells. The most important distinction is whether abnormal cells have stayed in place. In situ means the cells remain inside the lining where they started. Ductal carcinoma in situ (DCIS) is a stage 0, non-invasive cancer that cannot spread beyond the breast. Lobular carcinoma in situ (LCIS) is not cancer at all, but it signals a higher chance of breast cancer later. Invasive cancer has grown through that lining into the surrounding breast tissue, which is what allows it to reach lymph nodes or other parts of the body. Invasive ductal carcinoma is the most common breast cancer, making up about 70 to 80 percent of cases. Invasive lobular carcinoma is next, at about 10 to 15 percent. Lobular cancer cells lack a protein that holds cells together, so they tend to spread in thin lines rather than forming a firm lump. That can make lobular cancer harder to feel or see on a mammogram, and it is more often found in both breasts. The same medical label is also used for a few tumors outside the breast, most notably ductal adenocarcinoma of the pancreas and cystic growths in the pancreatic ducts. Those are different diseases with different tests and treatment, and this page focuses on the breast.

Causes & Risk Factors

Breast cancer develops when changes in a cell's DNA let it grow out of control. For most people, no single cause can be identified. Factors that raise the risk include older age, a previous breast cancer or certain benign breast conditions, dense breast tissue, radiation to the chest earlier in life, obesity and drinking alcohol. A longer lifetime exposure to estrogen also plays a role, such as starting periods early, reaching menopause late, having a first child later or never giving birth, and taking menopausal hormone therapy. Inherited changes in genes such as BRCA1 and BRCA2 raise the risk of breast cancer, as well as ovarian and some other cancers. Medullary breast cancer has a notable link to BRCA1: depending on the study, between about 3 and 35 percent of people with this type carry an inherited BRCA1 change, so a medullary diagnosis is one reason to discuss genetic counseling. Risk factors increase the odds of breast cancer but do not mean a person caused it, and many people with breast cancer have no known risk factor beyond age.

How It's Diagnosed

These tumors are often first noticed on a screening mammogram, an X-ray of the breast, or as a lump or other change a person or clinician finds. DCIS commonly shows up as an abnormal area on a mammogram without any symptoms. Ultrasound and breast MRI (magnetic resonance imaging, a scan that uses magnets rather than X-rays) can give more detail. MRI is especially useful for lobular cancer, since its thin, spreading pattern can be missed or underestimated on a mammogram. Only a biopsy confirms the diagnosis. A small sample of tissue, usually taken with a needle, is examined under a microscope to determine whether the cells are ductal, lobular or medullary, and whether they are in situ or invasive. LCIS is often found by chance in a biopsy done to check something else. For invasive cancer and DCIS, the lab also tests for hormone receptors, proteins that let estrogen or progesterone fuel the cancer's growth. About three in four breast cancers have at least one. Invasive cancers are also tested for HER2, a growth protein that some cancers make in excess. A cancer that lacks all three is called triple-negative; medullary cancers often fall in this group. Together with the tumor's size, its grade (how abnormal the cells look) and whether nearby lymph nodes are involved, these results set the stage and guide treatment. Imaging to look for spread is done when the stage or symptoms call for it.

Treatment Options

Treatment depends on the type, the stage and the receptor results, and most plans combine more than one approach. Local treatments act on the breast and nearby lymph nodes, while systemic treatments travel through the body to reach cancer cells that may have spread. LCIS usually needs no treatment of its own. If it is found on a needle biopsy, the area is sometimes removed to make sure nothing more serious is nearby, especially for the less common pleomorphic or florid forms. The main response is closer, lifelong screening, and some people choose medicine to lower their future risk. DCIS is nearly always treated, because there is no reliable way to tell which cases would become invasive. Most people can choose between a lumpectomy (breast-conserving surgery that removes the abnormal area with a margin of normal tissue) and a mastectomy, which removes the breast. Radiation usually follows a lumpectomy to lower the chance of the problem returning. If the DCIS is hormone receptor-positive, hormone therapy such as tamoxifen or an aromatase inhibitor may be offered. Studies are testing whether careful monitoring could replace treatment for some low-risk DCIS, but that is not yet standard. Invasive ductal, lobular and medullary cancers are usually treated with surgery to the breast and to one or more lymph nodes under the arm. A sentinel node biopsy removes only the first few nodes the cancer would reach; a larger lymph node dissection is used when more nodes are involved and carries a higher chance of lasting arm swelling. Radiation often follows. Systemic treatment is chosen by the cancer's biology. Hormone therapy, which blocks estrogen's effect on the cancer, lowers the risk of recurrence for receptor-positive cancers and is usually taken for years. HER2-positive cancers are treated with targeted drugs aimed at that protein. Chemotherapy is used for many higher-risk or triple-negative cancers, and immunotherapy, which helps the immune system attack the cancer, may be added for some triple-negative cancers. Some people receive systemic treatment before surgery to shrink the tumor. Breast reconstruction is an option for people who have a mastectomy.

What to Expect

The outlook varies widely with the type and especially the stage at diagnosis. Nearly all people with DCIS can be cured. For invasive breast cancer in the United States, about 99 percent of people whose cancer is confined to the breast are alive five years later, compared with about 87 percent when it has reached nearby lymph nodes and about 32 percent when it has spread to distant organs. These figures come from people diagnosed years ago and cannot predict any one person's course. Medullary cancer generally has a more favorable outlook than its aggressive appearance under the microscope would suggest. Active treatment typically spans several months. Surgery recovery usually takes a few weeks, radiation is often given on weekdays over several weeks, and chemotherapy brings tiredness and other side effects that come and go with each cycle. Hormone therapy is usually a daily pill continued for five years or longer, and its side effects, such as hot flashes and joint aches, are a common reason to review the plan rather than simply stop. After treatment, follow-up visits and yearly mammograms continue for the long term. Hormone receptor-positive cancers can return many years later, and lobular cancer sometimes recurs in unusual places such as the abdomen or the lining of the lungs, so new, persistent symptoms are worth reporting even long after treatment ends. People with LCIS have about 7 to 12 times the usual chance of developing invasive cancer in either breast, so they are usually advised to have clinical breast exams every 6 to 12 months alongside yearly mammograms, sometimes with MRI.

When to Seek Help

Arrange a visit with a clinician if you notice a new lump or thickening in the breast or armpit, dimpling or puckering of the skin, a nipple that turns inward, nipple discharge other than breast milk (especially if it is bloody or from one breast), red or scaly skin on the nipple, or a change in breast size or shape. Most breast lumps are not cancer, but they deserve evaluation rather than waiting. During chemotherapy, call your care team right away for a fever of 100.5 F (38 C) or higher, chills or other signs of infection, since treatment can weaken the body's defenses and infections can become serious quickly. After lymph node surgery, tell your care team promptly about new swelling, tightness or pain in the arm, as early treatment of lymphedema works best. After treatment ends, report new symptoms that persist, such as bone pain, a lasting cough, or abdominal swelling or discomfort, at a prompt visit rather than waiting for the next scheduled check.

Questions to Ask Your Doctor

  1. 1.Is this in situ or invasive, and what do the type, grade, receptor and HER2 results mean for my treatment?
  2. 2.Would breast MRI or other imaging help define how far this has spread, given the type I have?
  3. 3.What are the trade-offs between lumpectomy with radiation and mastectomy in my situation?
  4. 4.Should I see a genetic counselor about inherited risk, such as a BRCA1 or BRCA2 change?
  5. 5.What will follow-up and screening look like after treatment, and which symptoms should prompt me to call between visits?

Last reviewed • Oct 2026

Educational content, not medical advice.